Price movement over the last 24 hours
Alcon AG vs CarMax, Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while CarMax, Inc trades at $50.52 (market cap $7.24B). The key difference: Alcon AG is far larger — about 4.5× CarMax, Inc's market cap, and Alcon AG pays a 0.54% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| ALC | KMX | |
|---|---|---|
Market Cap | $32.69B | $7.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $68.38 |
52-Week Low | $62.02 | $30.88 |
Enterprise Value | $36.28B | $25.75B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
CarMax (KMX) trades at $51.05, up 0.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 earnings that beat expectations, with revenue growth and cost control supporting a net income margin of 0.84%. Recent news highlights insider buying and a four-pillar turnaround strategy under new CEO Keith Barr, though margins remain under pressure.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating and $48.91 price target below current levels, but improving cash flow and strategic initiatives offer potential upside. Key risks include persistent margin compression, high debt levels, and execution challenges in a competitive used car market.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →